HPV L1壳蛋白联合HPV、Survivin检测宫颈癌前病变的运用探讨

Discussion on application of joint detection of HPV L1 capsid protein,HPV,and Survivin in cervical precancerous lesion

目的:了解HPV L1壳蛋白联合HPV、Survivin检测在诊断宫颈癌前病变中的作用。方法:回顾性地对该医院妇科门诊2007年7月～2011年5月进行HPV L1壳蛋白联合HPV、Survivin检测的284例患者进行总结和分析。结果:HPV L1壳蛋白随着宫颈病变程度的加重呈现下降趋势,其在CINⅠ组和CINⅡ组中的阳性率显著高于对照组(P<0.05)。HPV病毒随着宫颈病变程度的加重呈现上升趋势,其在CINⅠ组、CINⅡ组、CINⅢ组和SCC组中的阳性率显著高于对照组(P<0.05)。Survivin随着宫颈病变程度的加重呈现上升趋势,其在CINⅢ组和SCC组中的阳性率显著高于对照组(P<0.05)。HPV L1壳蛋白和HPV病毒表达呈负相关,HPV病毒与Survivin表达呈正相关(P<0.05)。结论:HPV L1壳蛋白联合HPV、Survivin检测可以作为预测宫颈癌前病变进展的生物学标志物。

Objective： To understand the role of joint detection of human papillomavirus （HPV） L1 capsid protein, HPV, and Survivin in diagnosis of cervical precancerous lesion. Methods ： A total of 284 patients who received joint detection of HPV L1 capsid pro- tein, HPV, and Survivin in gynecological outpatient department of the hospital from July 2007 to May 2011 were summarized and analyzed retrospectively. Results ： The expression level of HPV L1 capsid protein showed a decreasing trend with aggravation of cervical lesions, the positive rates of HPV L1 capsid protein in cervical intraepithelial neoplasia （CIN） I group and CIN ]I group were statistically significantly higher than that in control group （P 〈 0. 05） . The expression level of ttPV showed an increasing trend with aggravation of cervical lesions, the positive rates of HPV in CIN I group, CIN I1 group, CIN m group, and squamous cell carcinoma （SCC） group were statistically sig- nificantly higher than that in control group （ P 〈 0. 05 ） . The expression level of Survivin showed an increasing trend with aggravation of cer- vical lesions, the positive rates of Survivin in CIN 111 group and SCC group were statistically significantly higher than that in control group （P 〈 0. 05 ） . HPV L1 capsid protein expression was negatively correlated with HPV expression, while HPV expression was positively correlated with Survivin expression （ P 〈 0. 05 ） . Conclusion： Joint detection of HPV L1 capsid protein, HPV, and Survivin can be used as a biological marker to predict progress of cervical precancerous lesion.